Form 8-K

8-K — CROSS COUNTRY HEALTHCARE INC

Accession: 0000950103-26-010760

Filed: 2026-07-17

Period: 2026-07-16

CIK: 0001141103

SIC: 7363 (SERVICES-HELP SUPPLY SERVICES)

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — dp250209_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: dp250209_8k.htm · Sequence: 1

false

0001141103

2026-07-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

Form 8-K

____________________________

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 16, 2026

____________________________

Cross Country

Healthcare, Inc.

(Exact name of registrant as specified in its charter)

____________________________

Delaware

0-33169

13-4066229

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

5201 Congress Avenue, Suite 160, Boca Raton,

FL 33487

(Address of principal executive offices) (Zip Code)

(561) 998-2232

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

____________________________

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

of Form 8-K):

☐ Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant

to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CCRN

NASDAQ Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote

of Security Holders

On July 16, 2026, Cross Country Healthcare, Inc., a Delaware corporation

(the “Company”) convened a special meeting of stockholders (the “Special Meeting”) to consider and

vote upon certain proposals related to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of May 6,

2026, by and among the Company, KL Criss Cross Intermediate, LLC, a Delaware limited liability company (“Parent”),

and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”),

pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger

as a wholly-owned subsidiary of Parent. As a result of the Merger, the Company will no longer be publicly held. In connection with closing

the Merger, the Company’s common stock will be delisted from the NASDAQ Stock Market LLC and deregistered under the Securities Exchange

Act of 1934, as amended.

There were 32,306,484

shares of common stock, par value $0.0001 per share, of CCRN (“Company Common Stock”), issued and outstanding as of

June 12, 2026, the record date for the Special Meeting (the “Record Date”). Each share of Company Common Stock was

entitled to one vote with respect to each proposal at the Special Meeting. At the Special Meeting, the holders of 23,378,853 shares of

Company Common Stock were present or represented by proxy, representing approximately 72.36% of the total outstanding shares of Company

Common Stock as of the Record Date, which constituted a quorum.

At the Special Meeting,

the following proposals were voted upon (each of which is described in greater detail in the definitive proxy statement filed by the Company

with the Securities and Exchange Commission on June 15, 2026 (the “Proxy Statement”)):

Proposal

1 – The Merger Agreement Proposal: To adopt the Merger Agreement.

Proposal

2 – The Advisory Merger-Related Compensation Proposal: To approve,

on an advisory (non-binding) basis, the compensation that may be paid or become payable by the Company to its named executive officers

that is based on or otherwise relates to the merger.

Proposal

3 – The Adjournment Proposal: To approve the adjournment of the special meeting, if necessary, to solicit additional proxies

if there are not sufficient votes to approve the Merger Agreement proposal.

Proposals 1 and 2 were

approved by the requisite vote of the Company’s stockholders. Because Proposal 1 was approved, a vote on the Adjournment Proposal

(Proposal 3) described in the Proxy Statement was not necessary. A summary of the voting results for each proposal is set forth below.

Proposal 1 – Merger Agreement Proposal

Votes For

Votes Against

Abstentions

Broker Non-Votes

23,356,105

12,309

10,439

Proposal 2 – Advisory Merger-Related

Compensation Proposal

Votes For

Votes Against

Abstentions

Broker Non-Votes

20,281,587

1,855,191

1,242,075

Proposal 3 – Adjournment Proposal

Because there were sufficient votes at the

time of the Special Meeting to approve the Merger Agreement Proposal, a vote was not called on the Adjournment Proposal.

Subject to the satisfaction or waiver of customary closing conditions,

including receipt of certain regulatory approvals, the Merger is expected to close in the third quarter of 2026.

Important Information and Where to Find It

This communication relates to a proposed Merger between the Company,

Parent and the other parties to the Merger Agreement. In connection with this proposed Merger, the Company filed a definitive proxy statement

on Schedule 14A with the SEC, and the definitive proxy statement was thereafter mailed to stockholders of the Company seeking their approval

of the Merger-related proposals. This communication is not a substitute for any proxy statement or other document the Company has filed

or may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ

THE DEFINITIVE PROXY STATEMENT, INCLUDING THE DOCUMENTS INCORPORATED BY REFERENCE INTO THE DEFINITIVE PROXY STATEMENT, AND OTHER DOCUMENTS

THAT HAVE BEEN AND MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN

IMPORTANT INFORMATION. Investors and security holders are able to obtain free copies of these documents and other documents filed with

the SEC by the Company through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by

the Company are available free of charge on the Company’s internet website at https://ir.crosscountryhealthcare.com/ or by contacting

the Company’s primary investor relations contact by email at jvogel@crosscountry.com or by phone at 561-237-8310.

The website addresses included herein are inactive textual references

only. The information contained on such websites is not incorporated into this Report.

Participants in the Solicitation

The Company, Parent, Merger Sub, their respective directors, and certain

of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed Merger.

Information about the directors and executive officers of the Company, their ownership of Company Common Shares, and the Company’s

transactions with related persons is set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was

filed with the SEC on March 10, 2026 in its definitive proxy statement on Schedule 14A for its 2026 Annual Meeting in the sections entitled

“Security Ownership of Certain Beneficial Owners and Management” and “Related Party Transactions”, which was filed

with the SEC on March 30, 2026, as amended by Amendment No. 1 thereto filed on April 2, 2026, certain of its Quarterly Reports on Form

10-Q, and certain of its Current Reports on Form 8-K.

These documents can be obtained free of charge from the sources indicated

above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests,

by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when

they become available.

No Offer or Solicitation

This communication is for

informational purposes only and is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to

buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in

which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such

jurisdiction.

Forward Looking Statements

This communication contains “forward-looking statements”

within the Private Securities Litigation Reform Act of 1995. Any statements contained in this communication that are not statements of

historical fact, including statements regarding the proposed Merger, including the expected timing and closing of the proposed Merger;

the Company’s ability to consummate the proposed Merger; the expected benefits of the proposed Merger and other considerations taken

into account by the Board in approving the proposed Merger; the amounts to be received by stockholders; and expectations for the Company

prior to and following the Closing of the proposed Merger, may be deemed to be forward-looking statements. All such forward-looking statements

are intended to provide management’s current expectations for the future of the Company based on current expectations and assumptions

relating to the Company’s business, the economy and other future conditions. Forward-looking statements generally can be identified

through the use of words such as “believes,” “anticipates,” “may,” “should,” “will,”

“plans,” “projects,” “expects,” “expectations,” “estimates,” “forecasts,”

“predicts,” “targets,” “prospects,” “strategy,” “signs,” and other words of

similar meaning in connection with the discussion of future performance, plans, actions or events. Because forward-looking statements

relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict. Such

risks and uncertainties include, among others: (i) the timing to consummate the proposed Merger, (ii) the risk that a condition of Closing

of the proposed Merger may not be satisfied or that the Closing of the proposed Merger might otherwise not occur, (iii) the risk that

a regulatory approval that may be required for the proposed Merger is not obtained or is obtained subject to conditions that are not anticipated,

(iv) the diversion of management time on transaction-related issues, (v) risks related to disruption of management time from ongoing business

operations due to the proposed Merger, (vi) the risk that any announcements relating to the proposed Merger could have adverse effects

on the market price of Company Common Shares, (vii) the risk that the proposed Merger and its announcement could have an adverse effect

on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with its suppliers and

customers, (viii) the occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the

Merger Agreement, including in circumstances requiring the Company to pay a termination fee, (ix) the risk that competing offers will

be made; (x) unexpected costs, charges or expenses resulting from the Merger, (xi) potential litigation relating to the Merger that could

be instituted against the parties to the Merger Agreement or their respective directors, managers, or officers, including the effects

of any outcomes related thereto, (xii) worldwide economic or political changes that affect the markets that the Company’s businesses

serve which could have an effect on demand for the Company’s services and impact the Company’s profitability, (xiii) effects

from global pandemics, epidemics, or other public health crises, (xiv) changes in marketplace conditions, such as alternative modes of

healthcare delivery, reimbursement, and customer needs, and (xv) disruptions in the global credit and financial markets, including diminished

liquidity and credit availability, changes in international trade agreements, including tariffs and trade restrictions, cyber-security

vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, costs of providing services, retention of key

employees, and outcomes of legal proceedings, claims and investigations. Accordingly, actual results may differ materially from those

contemplated by these forward-looking statements. Investors, therefore, are cautioned against relying on any of these forward-looking

statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Additional information

regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s

filings with the SEC, including the risks and uncertainties identified in Part I, Item 1A - Risk Factors of the Company’s Annual

Report on Form 10-K for the year ended December 31, 2025 and in the Company’s other filings with the SEC. The list of factors is

not intended to be exhaustive.

These forward-looking statements speak only as

of the date of this communication, and, except as may be required by applicable law, the Company does not assume any obligation to update

or revise any forward-looking statement made in this communication or that may from time to time be made by or on behalf of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CROSS COUNTRY HEALTHCARE, INC.

Date: July 17, 2026

By:

/s/ Kevin C. Clark

Name:

Kevin C. Clark

Title:

Co-Founder, Chairman and Chief Executive Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Jul. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 16, 2026

Entity File Number

0-33169

Entity Registrant Name

Cross Country

Healthcare, Inc.

Entity Central Index Key

0001141103

Entity Tax Identification Number

13-4066229

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5201 Congress Avenue

Entity Address, Address Line Two

Suite 160

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33487

City Area Code

561

Local Phone Number

998-2232

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

CCRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration